Physician profile
Marvin D Berman
NPI 1295783546
$2,589.29
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2022: $282 · 2023: $753 · 2024: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Education: $24.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.46 |
| Education | $24.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.08 | 2019-2024 | Linzess, Viberzi, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $211.37 | 2022-2024 | Entyvio |
| Janssen Biotech, INC. | $198.08 | 2022-2024 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $178.23 | 2019-2024 | |
| Covidien LP | $131.21 | 2019 | |
| Boston Scientific Corporation | $100.45 | 2024 | X-Tack Endoscopic Helix Tacking System |
| Pfizer INC. | $100.19 | 2023-2024 | |
| Organon LLC | $86.42 | 2023-2024 | Hadlima, Renflexis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.97 | 2019-2024 | Trulance |
| Ardelyx, INC. | $64.57 | 2024 | Ibsrela |
| Celltrion USA INC. | $48.75 | 2024 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $24.39 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $23.00 | 2024 | Voquezna |
| Celgene Corporation | $22.58 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.